Correction to: Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment

Affiliations

¹ The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel.
² Research Unit, Geha Mental Health Center and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
⁴ The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel. mgavish@technion.ac.il.

Published Erratum

Martin Gabay et al. Cell Mol Neurobiol. 2022 May.

. 2022 May;42(4):1265.

doi: 10.1007/s10571-021-01182-4.

¹ The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel.
² Research Unit, Geha Mental Health Center and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
⁴ The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel. mgavish@technion.ac.il.

No abstract available

Erratum for

Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment.
Gabay M, Weizman A, Zeineh N, Kahana M, Obeid F, Allon N, Gavish M. Gabay M, et al. Cell Mol Neurobiol. 2021 Jul;41(5):1019-1029. doi: 10.1007/s10571-020-00969-1. Epub 2020 Oct 6. Cell Mol Neurobiol. 2021. PMID: 33025416 Free PMC article.